Veradermics is a late-stage biopharmaceutical company founded by dermatologists developing therapeutics for aesthetic and dermatological conditions with large unmet medical needs. The company's lead product candidate, VDPHL01, is an oral extended-release formulation of minoxidil designed to treat pattern hair loss in both men and women, addressing a large and underserved patient population with inadequate existing treatment options. The company generates value through the clinical development and potential commercialization of differentiated drug candidates, with plans to pursue a direct-to-consumer and healthcare provider-focused commercial strategy if approved.